Trillium Therapeutics Receives Final Court Order Approving Arrangement
28 oct. 2021 17h00 HE
|
Trillium Therapeutics Inc.
CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
Trillium Securityholders Approve Acquisition by Pfizer
26 oct. 2021 17h15 HE
|
Trillium Therapeutics Inc.
CAMBRIDGE, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
Pfizer to Acquire Trillium Therapeutics Inc.
23 août 2021 06h45 HE
|
Trillium Therapeutics Inc.
Proposed acquisition strengthens Pfizer’s category leadership in Oncology with addition of next-generation, investigational immuno-therapeutics for hematological malignancies Expands innovative...
Trillium Therapeutics Reports Second Quarter 2021 Operating and Financial Results
13 août 2021 07h00 HE
|
Trillium Therapeutics Inc.
CAMBRIDGE, Mass., Aug. 13, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of...
Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in Combination With Azacitidine in TP53-Mutated Acute Myeloid Leukemia
09 août 2021 07h00 HE
|
Trillium Therapeutics Inc.
CAMBRIDGE, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of...
Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in Combination With Azacitidine and Venetoclax in TP53-Wild Type Acute Myeloid Leukemia
06 juil. 2021 07h00 HE
|
Trillium Therapeutics Inc.
CAMBRIDGE, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of...
Trillium Therapeutics Appoints Catherine Mackey, Ph.D., to Its Board of Directors
30 juin 2021 07h00 HE
|
Trillium Therapeutics Inc.
CAMBRIDGE, Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-621 in Combination With Doxorubicin in Leiomyosarcoma
29 juin 2021 07h00 HE
|
Trillium Therapeutics Inc.
CAMBRIDGE, Mass., June 29, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of...
Trillium Therapeutics Joins Russell 2000® and 3000® Indices
25 juin 2021 18h28 HE
|
Trillium Therapeutics Inc.
CAMBRIDGE, Mass., June 25, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
Trillium Announces Voting Results From the Annual General and Special Meeting of Shareholders
09 juin 2021 07h00 HE
|
Trillium Therapeutics Inc.
CAMBRIDGE, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) (the “Corporation”), a clinical stage immuno-oncology company developing innovative therapies for...